MOLECULAR EVENTS IN THE PATHOGENESIS OF KAPOSI'S SARCOMA
卡波西肉瘤发病机制中的分子事件
基本信息
- 批准号:2376967
- 负责人:
- 金额:$ 21.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-05-01 至 2000-02-29
- 项目状态:已结题
- 来源:
- 关键词:Kaposi's sarcoma biopsy complementary DNA enzyme activity enzyme induction /repression gene expression genetic library human subject immunocytochemistry in situ hybridization interferons molecular cloning molecular oncology mutant nuclear factor kappa beta nucleic acid sequence pathologic process phosphorylation protein kinase C translation factor vascular endothelium
项目摘要
KS is a polyclonal malignancy that occurs at high frequency in
subpopulations of HIV-infected individuals as well as in some non-HIV
infected populations. Attempts as identifying an infectious co-factor in
KS cells have been unfruitful, epidemiologic data suggesting such a co-
factor.
We have determined that KS cells differ dramatically from normal
endothelial cells in their responsiveness to agents that induce VCAM-1,
especially in their molecular responsiveness to double stranded RNA. This
is most likely due to differential activation of the double stranded RNA
activated protein kinase, PKR. This is a kinase that is important in the
host anti-viral response, and many viruses have evolved mechanisms to
subvert the antiviral activities of PKR. PKR is an IFN-responsive gene
that has recently been shown to be a tumor suppressor gene. We
hypothesize that functional alterations of PKR, possibly due to a viral
inhibitor in the KS cells, are important in the pathogenesis of KS. We
hypothesize that clinical responses to IFN might result from higher levels
of PKR protein overcoming some of the functional inhibition of PKRs tumor
suppressor function. We have demonstrated that microvascular endothelial
cells transfected with either a viral inhibitor of PKR function or a
mutant PKR that functionally inactivates wild type PKR develop a KS-like
phenotype, supporting the hypothesis that alteration of PKR function is
critical in the development of KS.
In this proposal, we will fully characterize PKR induction and activation
in KS cells compared to normal ECs. We will examine changes in
autophosphorylation, in phosphorylation of the translation factor eIF-
2alpha, and in activation of NF-kappaB in KS cells compared to normal ECs.
We will then identify the macromolecular components in KS cells that are
responsible for the functional differences.
We will also identify genes that are differentially expressed in KS cells
compared to normal and activated microvascular endothelial cells. cDNA
libraries will be created from cultured KS cells and from cultured skin
microvascular endothelial cells grown under identical conditions.
Differential screening of cloned genes will be undertaken to identify
genes expressed exclusively in the KS cells compared to normal endothelial
cells and compared to cytokine activated endothelial cells. Functional
assays of these genes will be done by expressing selected sequences in
cultured microvascular endothelial cells to see if they generate a KS
phenotype. In situ hybridization and immunohistochemistry will be done to
localize the expression of these genes in KS versus uninvolved tissue.
The relationship of these genes to altered PKR activity will also be
explored.
KS是一种多克隆恶性肿瘤,高发于
艾滋病毒感染者和一些非艾滋病毒感染者的亚群
受感染的人群。将尝试作为确定感染的辅助因素
KS细胞一直没有结果,流行病学数据表明这种共同的
因素。
我们已经确定KS细胞与正常细胞有显著的不同
内皮细胞对诱导VCAM-1的药物的反应性,
尤其是它们对双链RNA的分子反应性。这
很可能是由于双链RNA的差异激活所致
活化蛋白激酶,PKR。这是一种重要的激酶,在
宿主抗病毒反应,许多病毒已经进化出机制来
颠覆PKR的抗病毒活性。PKR是一种干扰素反应基因
最近发现这是一种肿瘤抑制基因。我们
假设PKR的功能改变,可能是由于病毒
抑制物在KS细胞中的表达,在KS的发病机制中起重要作用。我们
假设临床对干扰素的反应可能源于较高的水平
PKR蛋白克服PKR对肿瘤的部分功能抑制作用
抑制器功能。我们已经证明了微血管内皮细胞
转染有PKR功能的病毒抑制物或
功能失活野生型PKR的突变体PKR发展成KS样蛋白
表型,支持PKR功能改变是
在KS的发展中至关重要。
在这项提案中,我们将充分描述PKR的诱导和激活
KS细胞与正常内皮细胞比较。我们将研究以下方面的变化
在翻译因子eIF的磷酸化中,自动磷酸化-
2α,与正常内皮细胞相比,KS细胞中NF-kappaB的活化。
然后我们将确定KS细胞中的大分子成分
对职能上的差异负责。
我们还将识别在KS细胞中差异表达的基因
与正常和激活的微血管内皮细胞相比。Cdna
将从培养的KS细胞和培养的皮肤创建文库
微血管内皮细胞在相同条件下生长。
将对克隆的基因进行差异筛选,以确定
与正常内皮细胞相比,KS细胞中特异表达的基因
并与细胞因子激活的内皮细胞进行比较。功能性
这些基因的分析将通过表达选定的序列在
培养的微血管内皮细胞是否产生KS
表型。将进行原位杂交和免疫组织化学
定位这些基因在KS中的表达,而不是非受累组织。
这些基因与PKR活性改变的关系也将是
探索过了。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARGARET K OFFERMANN其他文献
MARGARET K OFFERMANN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARGARET K OFFERMANN', 18)}}的其他基金
SUBVERSION OF HOST ANTIVIRAL DEFENSES BY HHV8 VIRF
HHV8 VIRF 颠覆宿主抗病毒防御
- 批准号:
6513191 - 财政年份:1998
- 资助金额:
$ 21.39万 - 项目类别:
SUBVERSION OF HOST ANTIVIRAL DEFENSES BY HHV8 VIRF
HHV8 VIRF 颠覆宿主抗病毒防御
- 批准号:
2896730 - 财政年份:1998
- 资助金额:
$ 21.39万 - 项目类别:
SUBVERSION OF HOST ANTIVIRAL DEFENSES BY HHV8 VIRF
HHV8 VIRF 颠覆宿主抗病毒防御
- 批准号:
6376922 - 财政年份:1998
- 资助金额:
$ 21.39万 - 项目类别:
SUBVERSION OF HOST ANTIVIRAL DEFENSES BY HHV8 VIRF
HHV8 VIRF 颠覆宿主抗病毒防御
- 批准号:
2717589 - 财政年份:1998
- 资助金额:
$ 21.39万 - 项目类别:
SUBVERSION OF HOST ANTIVIRAL DEFENSES BY HHV8 VIRF
HHV8 VIRF 颠覆宿主抗病毒防御
- 批准号:
6173889 - 财政年份:1998
- 资助金额:
$ 21.39万 - 项目类别:
MOLECULAR EVENTS IN THE PATHOGENESIS OF KAPOSIS SARCOMA
卡波西斯肉瘤发病机制中的分子事件
- 批准号:
2111055 - 财政年份:1995
- 资助金额:
$ 21.39万 - 项目类别:
MOLECULAR EVENTS IN THE PATHOGENESIS OF KAPOSI'S SARCOMA
卡波西肉瘤发病机制中的分子事件
- 批准号:
2882422 - 财政年份:1995
- 资助金额:
$ 21.39万 - 项目类别:
MOLECULAR EVENTS IN THE PATHOGENESIS OF KAPOSI'S SARCOMA
卡波西肉瘤发病机制中的分子事件
- 批准号:
2111056 - 财政年份:1995
- 资助金额:
$ 21.39万 - 项目类别:
MOLECULAR EVENTS IN THE PATHOGENESIS OF KAPOSI'S SARCOMA
卡波西肉瘤发病机制中的分子事件
- 批准号:
2668011 - 财政年份:1995
- 资助金额:
$ 21.39万 - 项目类别:
CYTOKINE AND ADHESION MOLECULE EXPRESSION IN KAPOSI'S
卡波西氏细胞因子和粘附分子的表达
- 批准号:
2101057 - 财政年份:1994
- 资助金额:
$ 21.39万 - 项目类别:
相似海外基金
卵巣癌/子宮体癌における薬剤感受性メチル化診断キットの開発とLiquid Biopsyへの応用
卵巢癌/子宫内膜癌药物敏感甲基化诊断试剂盒的研制及其在液体活检中的应用
- 批准号:
24K02584 - 财政年份:2024
- 资助金额:
$ 21.39万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
グリオーマのliquid biopsyによるメチル化網羅的解析とprecision medicineへの応用
胶质瘤液体活检甲基化综合分析及其在精准医疗中的应用
- 批准号:
24K12271 - 财政年份:2024
- 资助金额:
$ 21.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Liquid biopsyを用いた炎症性腸疾患の早期診断法開発
液体活检炎症性肠病早期诊断方法的开发
- 批准号:
24K10595 - 财政年份:2024
- 资助金额:
$ 21.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
精神的長期ストレス児童の口腔細菌叢と唾液成分の解析:唾液 liquid biopsyを目指して
长期精神应激儿童口腔菌群和唾液成分分析:唾液液体活检
- 批准号:
24K13206 - 财政年份:2024
- 资助金额:
$ 21.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
MONALISA: A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis
MONALISA:一项 SIOPEN 实用临床试验,通过液体活检监测神经母细胞瘤复发 敏感性分析
- 批准号:
10103126 - 财政年份:2024
- 资助金额:
$ 21.39万 - 项目类别:
EU-Funded
A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis (MONALISA)
SIOPEN 通过液体活检敏感性分析 (MONALISA) 监测神经母细胞瘤复发的实用临床试验
- 批准号:
10110442 - 财政年份:2024
- 资助金额:
$ 21.39万 - 项目类别:
EU-Funded
Mutated human oncogene recombinant nucleosomes as reference materials for liquid biopsy
突变人癌基因重组核小体作为液体活检参考材料
- 批准号:
10090714 - 财政年份:2024
- 资助金额:
$ 21.39万 - 项目类别:
Collaborative R&D
肝細胞癌における術中門脈血を用いたliquid biopsyの検討
肝细胞癌术中门静脉血液体活检检查
- 批准号:
24K19404 - 财政年份:2024
- 资助金额:
$ 21.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Genetic diagnosis of vascular malformations by liquid biopsy and its application to precision medicine
液体活检对血管畸形的基因诊断及其在精准医疗中的应用
- 批准号:
23K09072 - 财政年份:2023
- 资助金额:
$ 21.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Breath biopsy technology targeting for volatile oxidized lipids
针对挥发性氧化脂质的呼吸活检技术
- 批准号:
23K06080 - 财政年份:2023
- 资助金额:
$ 21.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)